‡Number is misleading inasmuch as Arius announced in May 2008 that it was pursued by an unnamed suitor.
‡‡Premium relative to commencement of bidding.
‡‡‡To be liquidated by Deerfield following failed merger with Archemix; premium relative to 11/18/08 date of Archemix deal.
‡†Based on closing price 8/21/08, the day before KG announced initial buyout offer.
‡*Based on 11/20/08 close.
†Premium reaches 63% if earn-out met.
††Premium and deal value based on 0.45/sh of contingent payments.
†††Premium relative to 7/30/08 close, the day before BMY announced first buyout offer.
†*Price for 44% of DNA not already owned.
†‡7% discount to market price excludes contingent payments.
*199% premium to volume-weighted price during preceding 3 months.
**Deal value includes assumption of debt.
***Premium and deal value exclude contingent payouts.
*‡Premium relative to 1/26/09, the day before Astellas announced $16/sh offer.
*‡‡Price includes entire deal in three stages; 17% premium is the blended avg price of NVS’ purchases ($164) relative to ACL’s market price 4/4/08 immediately prior to announcement of first stage of deal.
*†Premium includes estimated value of contingent payouts, but listed deal value excludes them.
*††IntelliPharmaCeutics.
*†*Relative to MIL’s price before announcement that co. was for sale.